Matt brings more than 18 years of experience in drug development and manufacturing process development for a range of biological medicines across different therapeutic areas (Infectious Disease/Vaccine, Oncology, Cardiovascular Disease, Respiratory, Inflammation, and Autoimmune). Most recently, Matt was an Associate Director of R&D at MedImmune where he led a downstream process development group focused on commercial process optimization, oversaw MedImmune’s viral clearance program, and led multiple, cross-functional CMC teams in support of clinical programs. Matt received his Ph.D. in Chemical Engineering from the University of Virginia.
Bart manages business development, procurement and contract functions. Bart brings a strong scientific background and over a decade of broad biopharmaceutical experience. He has worked across academia, biotech start-ups, and large pharma to lead and execute a wide variety of deals. Most recently, he led partnering efforts for MedImmune’s Partnering and Strategy team, focusing on building MedImmune’s early-stage immune-biology biologics portfolio. Previously, he led diverse projects for MedImmune’s Portfolio Management and Strategy team. Before MedImmune, Bart led R&D teams at Amorfix Life Sciences as a scientist to develop and commercialize Alzheimer’s and vCJD blood-based diagnostics. Bart earned his PhD in Medical biophysics at the University of Toronto, and an MBA from MIT Sloan School of Management.
Lee brings more than two decades of experiences in GxP Quality Assurance and Compliance. Most recently, Lee was a Director of R&D Biologics Quality at MedImmune where he headed the operations quality to support the MedImmune pipeline including 3 BLA approvals. In addition, he was the QA lead for the WuXi-MedImmune Joint Venture. Prior to entering R&D Biologics Quality at MedImmune, he held a GMP Compliance role as a lead auditor. Before joining AstraZeneca in 2011, he held multiple quality and compliance positions with increasing responsibilities at Genentech, Takeda (formerly Millennium), and Pfizer (formerly Wyeth). Lee got his BS in Chemistry at the University of Maryland.
Yingping brings two decade of experiences in applying information/digital technology and automation to drug discovery and development from early discovery to commercial manufacturing. Most recently, Yingping was a Director of IT at MedImmune where she led a team defining and implementing IT strategy for various parts of the R&D. Before joining MedImmune in 2012, Yingping held multiple Lab Automation and IT roles with increasing responsibilities at Pfizer. Yingping is the author and co-author of more than two dozen original research papers in QSAR predictive modeling, image processing and lab automation. Yingping is a certified Agile Consultant driving delivery effectiveness. She received her M.S. in Electrical Engineer from the University of Pittsburgh.